With the increasing limitations of current therapeutics and new healthcare challenges, the need for more innovation is higher than ever, looking at pushing the boundaries of the druggable space.
At the moment only 10% of the druggable genome is currently targeted by FDA approved drugs with 75% of protein research still focusing on these well-known targets. This imply that there is a potential to increase tenfold the therapeutics options on the market. Not even mentioning the rise of technologies such as AI, synthetic biology etc… that can support truly disruptive innovations to be delivered to patients.
This event will review the potential for innovations in the field of gene and cell therapy, oligonucleotides therapeutics and post transcriptional approaches together with discussing the challenges on the way to their adoption in healthcare delivery.
